Transdermal drug delivery systems in the elderly;Dispositifs médicamenteux transdermiques chez le sujet âgé

NPG Neurologie - Psychiatrie - Geriatrie

Volumn 12, Issue 69, 2012, Pages 139-143

  Burlaud, A ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Elderly; Observance; Patch transdermique; Sujet g ; Transdermal patch

Indexed keywords

EID: 84861922263     PISSN: 16274830     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npg.2012.04.006     Document Type: Review

References (27)

1. Small G., Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Cur Med Res Opin 2007, 23:2705-2713.
2. http://www.fda.gov/default.htm.
3. Chan A.L.F., Chien Y.W., Lin S.J. Transdermal delivery of treatment for Alzheimer's disease. Development, clinical performance and future prospects. Drugs Aging 2008, 25:761-775.
4. http://pharmacie.hug-ge.ch/infomedic/utilismedic/patchs.pdf.
5. http://afssaps-prd.afssaps.fr/php/ecodex/index.php.
6. http://vidal.fr/.
7. http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-2950_neupro_.pdf.
8. Rosin R.A., Levine M.D., Peskind E. Transdermal nicotine for agitation in dementia. Am J Geriatr Psychiatry 2001, 9:443-444.
9. Carmel H., Sheitman B.B. Adjunctive transdermal nicotine reduced behavioral agitation in severe dementia. Am J Geriatr Psychiatry 2007, 15:449.
10. Priano L., Gsaco M.R., Mauro A. Transdermal treatment options for neurological disorders. Impact on the elderly. Drugs aging 2006, 23:357-375.
11. Agence Européenne du médicament. http://www.emea.europa.eu/.
12. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-10/versatis_-_ct-8107.pdf.
13. Durand C., Alhammad A., Willett K.C. Practical considerations for optimal transdermal drug delivery. Am J Health Syst Pharm 2012, 69:116-124.
14. Cummings J., Lefèvre G., Small G., Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007, 69:S10-S13.
15. Lefèvre G., Sedek G., Huang H.A., et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007, 47:471-478.
16. Prescrire Rédaction Fentanyl en dispositif transdermique une alternative à la morphine. Rev Prescrire 1998, 18:331-334.
17. Kaestli L.Z., Wasilewski-Rasca A.F., Bonnabry P., et al. Use of transdermal drug formulations in the elderly. Drugs Aging 2008, 25:269-280.
18. Meaume S., Senet P. Traitement et prévention du vieillissement cutané. Gérontologie Préventive 2009, 151-160. Masson, Issy-les-Moulineaux. C. Trivalle (Ed.).
19. White-Chu E.F., Reddy M. Dry skin in the elderly: complexities of a common problem. Clin Dermatol 2011, 29:37-42.
20. Murphy M., Carmichael A.J. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol 2000, 1:361-368.
21. Prescrire Rédaction Scopolamine la référence contre les râles agoniques. Rev Prescrire 2001, 21:252-255.
22. Ball A.M., Smith K.M. Optimizing transdermal drug therapy. Am J Health Syst Pharm 2008, 65:1337-1346.
23. Lee D.H., Choi Y.H., Cho K.H., et al. A case of rivastigmine toxicity caused by transdermal patch. Am J Emerg Med 2011, 29:695e1-695e2.
24. Prescrire Rédaction Dispositifs transdermiques contenant de l'aluminium: risques de brûlures. Rev Prescrire 2007, 27:191.
25. Blesa R., Ballard C., Orgogozo J.M., et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007, 69:S23-S28.
26. Allan L., Hays H., Jensen N.H., et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001, 322:1154-1158.
27. Nagy B., Brennan A., Brandtmüller A., et al. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry 2010, 26:483-494.